Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening Products

Early Switch From Cyclosporine To Sirolimus After Renal Transplantation Produces Sustained Improvement In Renal Function
BOSTON - Favorable 12-month outcomes are maintained through 30 months of follow-up when renal transplant patients are converted from a cyclosporine (CsA)-based regimen to a sirolimus (SRL)-based regimen three months post-transplant, according to results of the CONCEPT study announced here at the American Transplant Congress (ATC) 2009.
generic viagra online
AccuVein Vein Illuminator Receives European CE Mark
AccuVein LLC, maker of the AV300, the world"s first hand-held, non-contact vein illumination device, announced today that its medical device now carries a CE Mark, enabling the Company to commence European sales of AccuVein"s AV300.
News of the day
National Survey Shows 70% Of Women Have Experienced A Sexual Health Issue
A new survey released shows 70 percent of women report having experienced a sexual health issue, of which 22 percent felt very or extremely concerned. The survey also found that many women claim they would be comfortable talking to a health care provider about a sexual health issue, but less than one-fifth (18%) actually visited their health care provider when they experienced one.
Public Health

Cytori Reports Publication Of Cardiovascular Preclinical Study; Adipose Stem & Regenerative Cells Improve Function In Heart Attack Model

Cytori (NASDAQ: CYTX) announced publication of the first preclinical study to demonstrate adipose-derived stem and regenerative cells (ADRCs) significantly improved cardiac function after a heart attack. This preclinical cardiac cell therapy study was reported online ahead of print in the International Journal of Cardiology. The study was funded by Cytori Therapeutics and conducted at Tulane University. "Treatment of cardiovascular disease, which places one of the greatest burdens on our healthcare system, could be revolutionized by cell therapy," said Marc H. Hedrick, M.D., president of Cytori. "We observed a statistically significant improvement in heart function that contributed to our decision to proceed with our APOLLO study. Cardiovascular disease is the most advanced application in Cytori"s product pipeline and could eventually make a substantial contribution to our future commercial activities." The APOLLO study is the first clinical trial to investigate uncultured adipose-derived stem and regenerative cells in heart attacks in human patients. Enrollment was recently completed in APOLLO, a double blind, placebo controlled, safety and feasibility trial. Data are expected to be reported in early 2010. The APOLLO study is sponsored by Cytori and has incorporated the Company"s Celution® System to automate the processing of the patients" cells at the point of care. In Cytori"s preclinical study, 17 large animals (pigs) were treated with their own uncultured adipose-derived stem and regenerative cells immediately following induction of a severe myocardial infarction. Uncultured cells include a multitude of heterogeneous cell types that Cytori believes facilitate several therapeutic mechanisms. Several functional measurements within the study indicated statistically significant improvement in both heart function and structure. Cytori


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009